The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Sirolimus- vs Paclitaxel-Eluting Stents in De Novo Coronary Artery Lesions: The REALITY Trial: A Randomized Controlled Trial
Open accessAbstract
CONTEXT: Compared with bare metal stents, sirolimus-eluting and paclitaxel-eluting stents have been shown to markedly improve angiographic and clinical outcomes after percutaneous coronary revascularization, but their performance in the treatment of de novo coronary lesions has not been compared in a prospective multicenter study. OBJECTIVE: To compare the safety and efficacy of sirolimus-eluting vs paclitaxel-eluting coronary stents. DESIGN: Prospective, randomized comparative trial (the REALITY trial) conducted between August 2003 and February 2004, with angiographic follow-up at 8 months and clinical follow-up at 12 months. SETTING: Ninety hospitals in Europe, Latin America, and Asia. PATIENTS: A total of 1386 patients (mean age, 62.6 years; 73.1% men; 28.0% with diabetes) with angina pectoris and 1 or 2 de novo lesions (2.25-3.00 mm in diameter) in native coronary arteries. INTERVENTION: Patients were randomly assigned in a 1:1 ratio to receive a sirolimus-eluting stent (n = 701) or a paclitaxel-eluting stent (n = 685). MAIN OUTCOME MEASURES: The primary end point was in-lesion binary restenosis (presence of a more than 50% luminal-diameter stenosis) at 8 months. Secondary end points included 1-year rates of target lesion and vessel revascularization and a composite end point of cardiac death, Q-wave or non-Q-wave myocardial infarction, coronary artery bypass graft surgery, or repeat target lesion revascularization. RESULTS: In-lesion binary restenosis at 8 months occurred in 86 patients (9.6%) with a sirolimus-eluting stent vs 95 (11.1%) with a paclitaxel-eluting stent (relative risk [RR], 0.84; 95% confidence interval [CI], 0.61-1.17; P = .31). For sirolimus- vs paclitaxel-eluting stents, respectively, the mean (SD) in-stent late loss was 0.09 (0.43) mm vs 0.31 (0.44) mm (difference, -0.22 mm; 95% CI, -0.26 to -0.18 mm; P<.001), mean (SD) in-stent diameter stenosis was 23.1% (16.6%) vs 26.7% (15.8%) (difference, -3.60%; 95% CI, -5.12% to -2.08%; P<.001), and the number of major adverse cardiac events at 1 year was 73 (10.7%) vs 76 (11.4%) (RR, 0.94; 95% CI, 0.69-1.27; P = .73). CONCLUSION: In this trial comparing sirolimus- and paclitaxel-eluting coronary stents, there were no differences in the rates of binary restenosis or major adverse cardiac events. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00235092.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moses, J. W., Leon, M. B., Popma, J. J., Fitzgerald, P. J., Holmes, D. R., O'Shaughnessy, C., Caputo, R. P., Kereiakes, D. J., Williams, D. O., Teirstein, P. S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035071 · Cited by 4,224
Morice, M.-C., Serruys, P. W., Sousa, J. E., Fajadet, J., Ban Hayashi, E., Perin, M., Colombo, A., Schuler, G., Barragan, P., Guagliumi, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012843 · Cited by 4,033
Self-citationIakovou, I. (2005) · JAMA · doi:10.1001/jama.293.17.2126 · Cited by 3,132
A Polymer-Based, Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease
Stone, G. W., Ellis, S. G., Cox, D. A., Hermiller, J., O'Shaughnessy, C., Mann, J. T., Turco, M., Caputo, R., Bergin, P., Greenberg, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032441 · Cited by 2,749
Letter: Grading of angina pectoris.
Campeau, L. (1976) · Circulation · doi:10.1161/circ.54.3.947585 · Cited by 1,601
Unstable angina. A classification.
Braunwald, E. (1989) · Circulation · doi:10.1161/01.cir.80.2.410 · Cited by 1,366
Colombo, A., Drzewiecki, J., Banning, A., Grube, E., Hauptmann, K., Silber, S., Dudek, D., Fort, S., Schiele, F., Zmudka, K., et al. (2003) · Circulation · doi:10.1161/01.cir.0000086926.62288.a6 · Cited by 1,016
Self-citationSchofer, J., Schlüter, M., Gershlick, A. H., Wijns, W., Garcia, E., Schampaert, E., & Breithardt, G. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14462-5 · Cited by 955
Grube, E., Silber, S., Hauptmann, K. E., Mueller, R., Buellesfeld, L., Gerckens, U., & Russell, M. E. (2003) · Circulation · doi:10.1161/01.cir.0000047700.58683.a1 · Cited by 865
Stone, G. W., Ellis, S. G., Cox, D. A., Hermiller, J., O’Shaughnessy, C., Mann, J. T., Turco, M., Caputo, R., Bergin, P., Greenberg, J., et al. (2004) · Circulation · doi:10.1161/01.cir.0000127110.49192.72 · Cited by 759
Cited by
Boutron, I., Moher, D., Altman, D. G., Schulz, K. F., Ravaud, P., & for the CONSORT Group* (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-4-200802190-00008 · Cited by 2,292
Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis
Stettler, C., Wandel, S., Allemann, S., Kastrati, A., Morice, M. C., Schömig, A., Pfisterer, M. E., Stone, G. W., Leon, M. B., de Lezo, J. S., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61444-5 · Cited by 1,428
Self-citationKing, S. B., Smith, S. C., Hirshfeld, J. W., Jacobs, A. K., Morrison, D. A., Williams, D. O., 2005 WRITING COMMITTEE MEMBERS, Smith, S. C., Feldman, T. E., Hirshfeld, J. W., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.188208 · Cited by 1,014
Camenzind, E., Steg, P. G., & Wijns, W. (2007) · Circulation · doi:10.1161/circulationaha.106.666800 · Cited by 818
In-Stent Restenosis in the Drug-Eluting Stent Era
Dangas, G. D., Claessen, B. E., Caixeta, A., Sanidas, E. A., Mintz, G. S., & Mehran, R. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.07.028 · Cited by 803
Metadata
- Authors
- Morice, M.-C., Colombo, A., Meier, B., Serruys, P., Tamburino, C., Guagliumi, G., Sousa, E., Stoll, H.-P., & REALITY Trial Investigators, F. T.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2006-02-22
- Volume
- 295
- Issue
- 8
- Pages
- 895
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2120050284
- Cited by
- 458
- References
- 17
- FWCI
- 67.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sirolimus- vs Paclitaxel-Eluting Stents in De Novo Coronary Artery Lesions: The REALITY Trial: A Randomized Controlled Trial. https://app.cochat.ai/papers/10.1001/jama.295.8.895
- The paper
- Morice, M.-C., Colombo, A., Meier, B., Serruys, P., Tamburino, C., Guagliumi, G., Sousa, E., Stoll, H.-P., & REALITY Trial Investigators, F. T. (2006). Sirolimus- vs Paclitaxel-Eluting Stents in De Novo Coronary Artery Lesions: The REALITY Trial: A Randomized Controlled Trial. JAMA. https://doi.org/10.1001/jama.295.8.895
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.